Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Morelos, Cuernavaca, México.
Departamento de Ingeniería en Sistemas Ambientales, Instituto Politécnico Nacional: Escuela Nacional de Ciencias Biológicas, Ciudad de Mexico, México.
Biol Trace Elem Res. 2023 Jul;201(7):3152-3161. doi: 10.1007/s12011-022-03411-3. Epub 2022 Sep 8.
Childhood atopic dermatitis (AD) is a chronic and recurrent health problem that involves multiple factors, particularly immunological and environmental. We evaluated the impact of docosahexaenoic acid (DHA) supplementation on prenatal arsenic exposure on the risk of atopic dermatitis in preschool children as part of the POSGRAD (Prenatal Omega-3 fatty acid Supplements, GRowth, And Development) clinical trial study in the city of Morelos, Mexico. Our study population included 300 healthy mother-child pairs. Of these, 146 were in the placebo group and 154 in the supplement group. Information on family history, health, and other variables was obtained through standardized questionnaires used during follow-up. Prenatal exposure to arsenic concentrations, which appear in maternal urine, was measured by inductively coupled plasma optical emission spectrometry. To assess the effect of prenatal arsenic exposure on AD risk, we ran a generalized estimating equation model for longitudinal data, adjusting for potential confounders, and testing for interaction by omega-3 fatty acid supplementation during pregnancy. The mean and SD (standard deviation) of arsenic concentration during pregnancy was 0.06 mg/L, SD (0.04 mg/L). We found a marginally significant association between prenatal arsenic exposure and AD (OR = 1.12, 95% CI: 0.99, 1.26); however, DHA supplementation during pregnancy modified the effect of arsenic on AD risk (p < 0.05). The results of this study strengthen the evidence that arsenic exposure during pregnancy increases the risk of atopic dermatitis early in life. However, supplementation with omega-e fatty acids during pregnancy could modify this association.
儿童特应性皮炎（AD）是一种慢性和复发性健康问题，涉及多个因素，特别是免疫和环境因素。我们评估了二十二碳六烯酸（DHA）补充剂对产前砷暴露对学龄前儿童特应性皮炎风险的影响，这是墨西哥莫雷洛斯州 POSGRAD（产前欧米伽-3 脂肪酸补充剂、生长和发育）临床试验研究的一部分。我们的研究人群包括 300 对健康的母婴对。其中，146 名在安慰剂组，154 名在补充剂组。通过在随访期间使用的标准化问卷获得了有关家庭史、健康和其他变量的信息。通过电感耦合等离子体光发射光谱法测量了出现在母亲尿液中的产前砷浓度。为了评估产前砷暴露对 AD 风险的影响，我们针对纵向数据运行了广义估计方程模型，调整了潜在的混杂因素，并通过怀孕期间补充欧米伽-3 脂肪酸检验了相互作用。怀孕期间砷浓度的平均值和标准差（SD）为 0.06 毫克/升，SD（0.04 毫克/升）。我们发现产前砷暴露与 AD 之间存在边缘显著关联（OR=1.12，95%CI：0.99，1.26）；然而，怀孕期间 DHA 补充剂改变了砷对 AD 风险的影响（p<0.05）。这项研究的结果加强了证据，表明怀孕期间砷暴露会增加生命早期特应性皮炎的风险。然而，怀孕期间补充欧米伽-3 脂肪酸可能会改变这种关联。
